Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Pharmacol Ther ; 177: 44-55, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28223234

ABSTRACT

Advanced glycation end products (AGEs) and their receptor have been implicated in the progressions of many intractable diseases, such as diabetes and atherosclerosis, and are also critical for pathologic changes in chronic degenerative diseases, such as Alzheimer's disease, Parkinson's disease, and alcoholic brain damage. Recently activated macrophages were found to be a source of AGEs, and the most abundant form of AGEs, AGE-albumin excreted by macrophages has been implicated in these diseases and to act through common pathways. AGEs inhibition has been shown to prevent the pathogenesis of AGEs-related diseases in human, and therapeutic advances have resulted in several agents that prevent their adverse effects. Recently, anti-inflammatory molecules that inhibit AGEs have been shown to be good candidates for ameliorating diabetic complications as well as degenerative diseases. This review was undertaken to present, discuss, and clarify current understanding regarding AGEs formation in association with macrophages, different diseases, therapeutic and diagnostic strategy and links with RAGE inhibition.


Subject(s)
Glycation End Products, Advanced/metabolism , Macrophages/metabolism , Humans , Inflammation/metabolism , Neurodegenerative Diseases/metabolism , Receptor for Advanced Glycation End Products/metabolism
2.
J Proteome Res ; 14(1): 214-23, 2015 Jan 02.
Article in English | MEDLINE | ID: mdl-25384129

ABSTRACT

Microglial activation in the central nervous system is a key event in the neuroinflammation that accompanies neurodegenerative diseases such as Alzheimer's disease (AD). Among cytokines involved in microglial activation, amyloid ß (Aß) peptide is known to be a key molecule in the induction of diverse inflammatory products, which may lead to chronic inflammation in AD. However, proteomic studies of microglia in AD are limited due to lack of proper cell or animal model systems. In this study, we performed a proteomic analysis of Aß-stimulated human microglial cells using SILAC (stable isotope labeling with amino acids in cell culture) combined with LC-MS/MS. Results showed that 60 proteins increased or decreased their abundance by 1.5 fold or greater. Among these, ER-resident proteins such as SERPINH1, PDIA6, PDIA3, and PPIB were revealed to be key molecular biomarkers of human microglial activation by validation of the proteomic results by immunostaining, PCR, ELISA, and Western blot. Taken together, our data suggest that ER proteins play an essential role in human microglial activation by Aß and may be important molecular therapeutic targets for treatment of AD.


Subject(s)
Amyloid beta-Peptides/physiology , Endoplasmic Reticulum/metabolism , Membrane Proteins/metabolism , Microglia/physiology , Proteome/metabolism , Alzheimer Disease/metabolism , Amino Acid Sequence , Animals , Biomarkers/metabolism , Cell Line , Gene Expression , Gene Ontology , Humans , Mice , Molecular Sequence Data , Protein Interaction Mapping , Proteome/genetics , Proteomics , Tandem Mass Spectrometry
3.
J Alzheimers Dis ; 36(2): 321-34, 2013.
Article in English | MEDLINE | ID: mdl-23603400

ABSTRACT

Alzheimer's disease (AD) is characterized by progressive memory loss accompanied by synaptic and neuronal degeneration. Although research has shown that substantial neurodegeneration occurs even during the early stages of AD, the detailed mechanisms of AD pathogenesis are largely unknown because of difficulties in diagnosis and limitations of the analytical methods. The 5XFAD mouse model harbors five early-onset familial AD (FAD) mutations and displays substantial amyloid plaques and neurodegeneration. Here, we use quantitative mass spectrometry to identify proteome-wide changes in the 5XFAD mouse hippocampus during the early stages of AD pathology. A subset of the results was validated with immunoblotting. We found that the 5XFAD mice display higher expression of ApoE, ApoJ (clusterin), and nicastrin, three important proteins in AD that are known to participate in amyloid-ß processing and clearance, as well as the neurological damage/glial marker protein GFAP and other proteins. A large subset of the proteins that were up- or downregulated in 5XFAD brains have been implicated in neurological disorders and cardiovascular disease, suggesting an association between cardiovascular disease and AD. Common upstream regulator analysis of upregulated proteins suggested that the XBP1, NRF2, and p53 transcriptional pathways were activated, as was IGF-1R signaling. Protein interactome analysis revealed an interconnected network of regulated proteins, with two major sub-networks centered on AßPP processing membrane complexes and mitochondrial proteins. Together with a recent study on the transcriptome of 5XFAD mice, our study allows a comprehensive understanding of the molecular events occurring in 5XFAD mice during the early stages of AD pathology.


Subject(s)
Alzheimer Disease/pathology , Gene Expression Regulation/genetics , Hippocampus/metabolism , Proteome/metabolism , Alzheimer Disease/genetics , Amyloid Precursor Protein Secretases/metabolism , Amyloid beta-Protein Precursor/genetics , Animals , Chromatography, Liquid , Disease Models, Animal , Glial Fibrillary Acidic Protein/metabolism , Hippocampus/pathology , Humans , Membrane Glycoproteins/metabolism , Mice , Mutation/genetics , Presenilin-1/genetics , Proteome/genetics , Signal Transduction/genetics , Tandem Mass Spectrometry , Transcription Factors/metabolism
4.
Biochem Biophys Res Commun ; 434(1): 87-94, 2013 Apr 26.
Article in English | MEDLINE | ID: mdl-23542466

ABSTRACT

Auditory fear conditioning is a well-characterized rodent learning model where a neutral auditory cue is paired with an aversive outcome to induce associative fear memory. The storage of long-term auditory fear memory requires long-term potentiation (LTP) in the lateral amygdala and de novo protein synthesis. Although many studies focused on individual proteins have shown their contribution to LTP and fear conditioning, non-biased genome-wide studies have only recently been possible with microarrays, which nevertheless fall short of measuring changes at the level of proteins. Here we employed quantitative proteomics to examine the expression of hundreds of proteins in the lateral amygdala in response to auditory fear conditioning. We found that various proteins previously implicated in LTP, learning and axon/dendrite growth were regulated by fear conditioning. A substantial number of proteins that were regulated by fear conditioning have not yet been studied specifically in learning or synaptic plasticity.


Subject(s)
Conditioning, Psychological/physiology , Fear/physiology , Proteomics/methods , Acoustic Stimulation , Amygdala/physiology , Animals , Male , Memory, Long-Term/physiology , Nerve Tissue Proteins/physiology , Protein Interaction Maps , Rats , Rats, Sprague-Dawley , Tandem Mass Spectrometry
SELECTION OF CITATIONS
SEARCH DETAIL
...